NEW YORK, Feb. 17 (GenomeWeb News) - Atugen has extended by one year its non-exclusive target validation and license agreement with Altana Pharma, the company said yesterday.
The extended deal, originally signed in 2001, calls for Atugen to continue validating potential targets supplied by Altana. The agreement provides a license to Altana's gene-silencing and oligonucleotide-delivery technologies.
Financial details were not disclosed.